N-desethyloxybutynin (NT0502) / Aytu BioPharma - LARVOL DELTA

Neos Therapeutics Reports Second Quarter 2020 Financial Results (GlobeNewswire) - "Phase 1 single ascending and multiple ascending dose trial to begin in fourth quarter of 2020: The Company plans to initiate a Phase 1 clinical trial for NT0502, for the treatment of sialorrhea in patients with neurological conditions, in the fourth quarter of 2020. The multi-part study will include single ascending and multiple ascending dose cohorts."

New P1 trial • CNS Disorders

Neos Therapeutics Announces Issuance of New U.S. Methods of Use Patent for N-desethyloxybutynin (GlobeNewswire, Neos Therapeutics, Inc.) - "Neos Therapeutics, Inc...today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No 10,610,507, which is directed to methods of treating sialorrhea by administering N-desethyloxybutynin, the active pharmaceutical ingredient in NT0502....The patent, assigned to Neos Therapeutics, is not expected to expire before November 2032....'The issuance of this patent further supports our efforts to explore the potential of NT0502 to treat sialorrhea in patients with neurological disorders, particularly Parkinson’s Disease'....'We remain on track to initiate a Phase 1 single ascending and multiple ascending dose clinical trial of NT0502 in the second half of 2020, and look forward to reporting the data from this trial.'"

New P1 trial • Patent

Neos completes dosing in phase 1 trial of anti-drooling treatment NT0502 in healthy volunteers (ALS News Today) - “Dosing of healthy volunteers has been completed in a Phase 1 clinical trial evaluating Neos Therapeutics‘ experimental therapy NT0502 for chronic sialorrhea (excessive drooling), a common problem in people with amyotrophic lateral sclerosis (ALS)….Data from the trial – expected to become available within the first quarter of 2020…”

P1 data • Trial status